Cingulate Inc
USUSDCingulate Inc (US:CING) — Biotechnology: Pharmaceutical Preparations. Numărul de burse pe care se tranzacționează acțiunile companiei: 1. Pe această pagină — preț și grafic, dividende, principalii deținători și istoricul numărului de acțiuni.
Despre companie
- Site web
- cingulate.com
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sediu central
- KANSAS CITY, United States
- Director general
- Dr. Shane J. Schaffer Pharm.D.
- Angajați
- 14
- Acțiuni în circulație
- 14.54 mil. la 2026-08-12
- Free float
- 14.2 mil.
- Capitalizare de piață
- 69.22 mil. USD
- Insideri
- 28.29%
- Investitori instituționali
- 12.59%
- Industrie (SIC)
- Pharmaceutical Preparations
Descriere
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Burse și simboluri
| Bursă | Simbol | Monedă | Preț | Tip |
|---|---|---|---|---|
| US USA Stocks | CING | USD | 4.88 +0.21% | acțiuni ordinare |
Dividende
Nu s-au găsit plăți de dividende (verificat 09.10.2026). Probabil că societatea nu plătește dividende.
Știri din această săptămână
Încă nu există știri de pe site-ul companiei.
Cei mai mari acționari
| Deținător | Participație | Acțiuni | Data raportului |
|---|---|---|---|
| Vanguard Capital Managem… | 3.93% | 570 873 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.71% | 394 555 | 2026-06-30 |
| Chicago Partners Investm… | 1.3% | 188 429 | 2026-06-30 |
| Raymond James Financial,… | 1.15% | 166 898 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.1% | 160 396 | 2026-06-30 |
| Kestra Advisory Services… | 1.04% | 151 500 | 2026-06-30 |
| Geode Capital Management… | 0.99% | 144 636 | 2026-06-30 |
| Renaissance Technologies… | 0.88% | 127 500 | 2026-06-30 |
| Vanguard Fiduciary Trust… | 0.54% | 79 160 | 2026-06-30 |
| Fidelity Concord Street… | 0.47% | 68 675 | 2026-07-31 |
| Blackrock Inc. | 0.37% | 53 130 | 2026-06-30 |
| Bcv Asset Management Inc… | 0.35% | 51 200 | 2026-06-30 |
| State Street Corporation | 0.33% | 47 888 | 2026-06-30 |
| iShares Trust-iShares Mi… | 0.19% | 27 806 | 2026-08-31 |
| Fidelity Concord Street… | 0.15% | 22 533 | 2026-07-31 |
| Fidelity Concord Street… | 0.13% | 18 514 | 2026-07-31 |
| SCHAFFER SHANE J. (Chief… | ≈0.1% | 14 251 | 2026-03-09 |
| CALLAHAN JENNIFER L. (Ch… | ≈0.1% | 13 961 | 2026-03-09 |
| Fidelity Concord Street… | 0.08% | 11 888 | 2026-07-31 |
| VANGUARD Inst. INDEX Fd.… | 0.07% | 10 246 | 2026-06-30 |
| BRAMS MATTHEW (Officer) | ≈0.06% | 8 157 | 2026-03-09 |
| VANGUARD VALLEY FORGE FU… | 0.04% | 5 676 | 2026-06-30 |
| SILVA RAUL R. (Officer) | ≈0.03% | 4 645 | 2026-03-09 |
| PATEL NILAY DAHYABHAI J.… | ≈0.02% | 3 389 | 2026-03-09 |
| EQ Advisors Trust-1290 V… | 0.01% | 1 871 | 2026-06-30 |
| MYERS LAURIE (Chief Oper… | — | 0 | 2024-08-15 |
| HARGROVES THOMAS JEFFREY… | — | — | 2026-02-13 |
| WERTH PETER J. (Director… | — | — | 2026-02-06 |
